The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1695
February 5, 2024
View Complete Issue         Table of Contents 2019 
IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure
February 5, 2024 (Issue: 1695)
Ferric carboxymaltose (Injectafer – American Regent) is now FDA-approved for IV treatment of iron deficiency in adults with New York Heart Association (NYHA) class II/III heart failure to improve exercise capacity. Iron deficiency is present in...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: IV Ferric Carboxymaltose (Injectafer) for Iron Deficiency in Heart Failure
Article code: 1695d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.